Home/Filings/4/0001140361-22-039911
4//SEC Filing

Ekman Lars 4

Accession 0001140361-22-039911

CIK 0001559053other

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 9:31 PM ET

Size

13.9 KB

Accession

0001140361-22-039911

Insider Transaction Report

Form 4
Period: 2022-11-01
Ekman Lars
Director
Transactions
  • Sale

    Ordinary Shares, par value $0.01 per share

    2022-11-01$62.01/sh9,143$566,9536,933 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2022-11-01$62.91/sh1,717$108,0135,216 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-11-0115,83331,668 total
    Exercise: $6.41Exp: 2023-01-29Ordinary Shares (15,833 underlying)
  • Sale

    Ordinary Shares, par value $0.01 per share

    2022-11-01$64.94/sh1,661$107,868243 total
  • Exercise/Conversion

    Ordinary Shares, par value $0.01 per share

    2022-11-01$6.41/sh+15,833$101,49016,076 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2022-11-01$64.26/sh3,312$212,8241,904 total
Footnotes (6)
  • [F1]The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The transaction was executed in multiple trades in prices ranging from $61.56 to $62.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4.
  • [F3]The transaction was executed in multiple trades in prices ranging from $62.57 to $63.27, inclusive.
  • [F4]The transaction was executed in multiple trades in prices ranging from $63.83 to $64.815, inclusive.
  • [F5]The transaction was executed in multiple trades in prices ranging from $64.86 to $65.16, inclusive.
  • [F6]The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately three months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.

Documents

1 file

Issuer

PROTHENA CORP PUBLIC LTD CO

CIK 0001559053

Entity typeother

Related Parties

1
  • filerCIK 0001376117

Filing Metadata

Form type
4
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 9:31 PM ET
Size
13.9 KB